Antihemophilic Factor (Recombinant [Porcine Sequence])

Name: Antihemophilic Factor (Recombinant [Porcine Sequence])

How is this medicine (Antihemophilic Factor) best taken?

Use this medicine as ordered by your doctor. Read all information given to you. Follow all instructions closely.

  • It is given as a shot into a vein.

What do I do if I miss a dose?

  • Call your doctor to find out what to do.

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.


(an tee hee moe FIL ik FAK tor ree KOM be nant POR sine SEE kwens)

Index Terms

  • AHF (Recombinant [Porcine Sequence])
  • Factor VIII (Recombinant [Porcine Sequence])
  • pFVIII
  • rAHF
  • rpFVIII


Allow vial and diluent to warm to room temperature before reconstitution. Gently swirl vial in a circular motion after adding diluent until dissolved.


Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Store the original package to protect from light. Use within 3 hours after reconstitution; discard any unused solution if not used within 3 hours after reconstitution.


Concerns related to adverse effects:

• Antibody formation: Formation of antiporcine factor VIII antibodies has occurred; monitor patients for the development of antibodies. Suspect an antiporcine factor VIII antibody if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration. If inhibitory antibodies are suspected and there is a lack of clinical response, consider other therapy.

• Hypersensitivity reactions: May occur; discontinue immediately if allergic or anaphylactic-type reactions occur.

Dosage form specific issues:

• Hamster protein: May contain trace amounts of hamster proteins.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer’s labeling.

• Sucrose: May contain sucrose.

Other warnings/precautions:

• Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Have patient report immediately to prescriber dizziness, passing out, severe loss of strength and energy, nausea, vomiting, agitation, burning or numbness feeling, or shortness of breath (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.